Global burden and trends of gout incidence and prevalence.
10.1097/CM9.0000000000003631
- Author:
Shuai JIN
1
;
Yuhan WANG
2
;
Shuangtong YAN
3
;
Xiaomin FU
2
;
Xiaodong HU
2
;
Zhaohui LYU
2
;
Hongzhou LIU
3
Author Information
1. School of Biology and Engineering (School of Health Medicine Modern Industry), Guizhou Medical University, Guiyang, Guizhou 561113, China.
2. Department of Endocrinology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
3. Department of Endocrinology, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.
- Publication Type:Journal Article
- Keywords:
Body mass index;
China;
DALYs;
Global burden of disease;
Gout;
Kidney dysfunction;
Prediction
- MeSH:
Humans;
Gout/epidemiology*;
Male;
Female;
Incidence;
Middle Aged;
Prevalence;
China/epidemiology*;
Adult;
Risk Factors;
Aged;
Global Burden of Disease;
Disability-Adjusted Life Years;
Young Adult;
Adolescent;
Quality-Adjusted Life Years
- From:
Chinese Medical Journal
2025;138(23):3153-3162
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Gout is a chronic disease primarily caused by elevated urate levels, severely affecting joint health. Its global distribution varies, and updated data for China are lacking. This study aimed to analyze the current burden and trends of gout globally and in China, examining the burden by gender, age, and risk factors while providing future predictions.
METHODS:This descriptive epidemiological secondary analysis utilized data from the Global Burden of Disease, Injuries, and Risk Factors (GBD) 2021 study. Age-standardized incidence rate (ASIR), prevalence rate (ASPR), and disability-adjusted life years (DALYs) rates (ASDR) were used to assess the gout burden. Trends from 1990 to 2021 were analyzed across global regions, genders, and sociodemographic index (SDI) levels. The burden in China was further examined by gender, age, and associated risk factors. The Bayesian age-period-cohort (BAPC) model was used to predict future trends. Gout burden in China and the United States was compared.
RESULTS:In 2021, gout affected 57 million people globally, with 9.4 million new cases and 1.75 million DALYs. From 1990 to 2021, the ASIR, ASPR, and ASDR increased by 17.2%, 21.9%, and 21.3%, respectively. Males experienced a significantly higher burden, with greater ASIR, ASPR, and ASDR increasing with higher SDI levels. In China, male ASIR, ASPR, and ASDR were over 2.8 times those of females, and the burden increased with age. In 2021, 31.4% of gout-related DALYs in China were attributed to high body mass index and 7.6% to kidney dysfunction. Between 1990 and 2021, the high body mass index-related burden of gout rose annually for both genders, while the kidney dysfunction-related gout burden remained stable. By 2050, the burden of gout in China is expected to continue increasing, with a slower rise in females and a decline in males after an initial increase. However, the overall burden will remain substantial. In comparison, the gout burden will be higher in the United States than in China.
CONCLUSIONS:Gout is becoming a significant health burden globally and in China, particularly among Chinese males and older individuals. With the aging population and lifestyle changes exacerbating the issue, effective strategies and measures are essential to prevent or reduce gout-related health issues.
